Amendments to the Claims:

This listing of claims will replace all prior versions, and listings, of claims in the application:

Listing of the Claims:

1. (Currently Amended) A method of enriching chaperone protein complexes from a sample comprising chaperone protein complexes, said method comprising the steps of
   (a) subjecting the sample to free solution isoelectric focusing in the presence of a chaotropic agent; and
   (b) collecting one or more fractions with a pH from pH 4.5 to 6.5 which are enriched in chaperone protein complexes.

2. (Canceled)

3. (Currently Amended) The method of claim 1, wherein said step of subjecting the sample to free solution isoelectric focusing in the presence of a chaotropic agent comprises
   (i) forming a pH gradient that comprises a pH value in the range from pH 4 to pH 7 in a matrix comprising charged buffer particles; and
   (ii) electrophoresing the sample through the pH gradient in the matrix for a period of time until the chaperone protein complexes cease to migrate within the pH gradient.

4-8. (Canceled)

9. (Currently Amended) The method of claim 3, wherein said matrix comprises 6 M urea, 0.5% ~~Triton X-100~~ octylphenol ethylene oxide condensate, 0.5% ~~Triton X-114~~ octylphenoxypoly (ethyleneoxy) ethanol, 0.5% ~~Igepal CA-630~~ tert-octylphenoxy poly(oxyethylene)ethanol, 5 mM Tris/Cl (pH 7.4), and 5 mM NaCl.

10. (Currently Amended) A method of making a composition enriched with chaperone protein complexes from a plurality of cells, said method comprising the steps of:
   (a) making a cell lysate by lysing the cells with a buffer consisting of 10 mM Tris/Cl, 10 mM NaCl, 0.1% ~~Triton X-100~~ octylphenol ethylene oxide condensate, 0.1% ~~Triton X-114~~ octylphenoxypoly (ethyleneoxy) ethanol, 0.1% ~~Igepal CA-630~~ tert-octylphenoxy poly(oxyethylene)ethanol, 2 μg/ml

leupeptin, 1 μg/ml pepstatin A, and 0.5 mM phenylmethylsulfonyl fluoride;

(b) dialyzing the cell lysate from (a) into a buffer consisting of 5 mM Tris/Cl, 5 mM NaCl, 0.05% ~~Triton X-100~~ octylphenol ethylene oxide condensate, 0.05% ~~Triton X-114~~ octylphenoxypoly (ethyleneoxy) ethanol, 0.05% ~~Igepal CA-630~~ tert-octylphenoxy poly(oxyethylene)ethanol;

(c) dialyzing the cell lysate from (b) into a buffer consisting of 2.5 mM Tris/Cl, 2.5 mM NaCl, 0.025% ~~Triton X-100~~ octylphenol ethylene oxide condensate, 0.025% ~~Triton X-114~~ octylphenoxypoly (ethyleneoxy) ethanol, 0.025% ~~Igepal CA-630~~ (octylphenoxy) polyethoxyethanol;

(d) dialyzing the cell lysate from (c) into a buffer consisting of 1.25 mM Tris/Cl, 1.25 mM NaCl, 0.012% ~~Triton X-100~~ octylphenol ethylene oxide condensate, 0.012% ~~Triton X-114~~ octylphenoxypoly (ethyleneoxy) ethanol, 0.012% ~~Igepal CA-630~~ tert-octylphenoxy poly(oxyethylene)ethanol;

(e) dialyzing the cell lysate from (d) into water;

(f) adding the cell lysate from (e) to a solution comprising urea and ~~ROTOLYTES®~~ ampholytes;

(g) forming a pH gradient that comprises a pH value in the range from pH 4 to pH 7 in a buffer comprising 6M urea, 0.4% ~~Triton X-100~~ octylphenol ethylene oxide condensate, 0.4% ~~Triton X-114~~ octylphenoxypoly (ethyleneoxy) ethanol, 0.4% ~~Igepal CA-630~~ tert-octylphenoxy poly(oxyethylene)ethanol and 30 ml of ~~ROTOLYTES®~~ ampholytes;

(h) electrophoresing the cell lysate (f) through the pH gradient in the matrix with a voltage of 500 to 2000 volts for 5 hours;

(i) collecting one or more fractions with a pH from pH 4.5 to 6.5; and

(j) dialyzing the fractions against a solution comprising phosphate buffered saline.

11. (Currently Amended) A pharmaceutical composition comprising a sample enriched in chaperone protein complexes, and a pharmaceutically acceptable excipient, wherein the sample is prepared by a method comprising:

(a) subjecting a solution comprising chaperone protein complexes and a plurality of different proteins to isoelectric focusing in the presence of a chaotropic agent, and

(b) collecting one or more fractions with a pH from pH 4.5 to 6.5; wherein at least some of the proteins in the solution are present in fractions other than fractions of pH 4.5 to pH 6.5; wherein the collected fractions comprise a mixture of chaperone protein complexes;

(c) wherein said chaperone protein complexes in said sample are not purified to homogeneity.

12-17. (Canceled)

18. (Original) The pharmaceutical composition of claim 11, wherein said sample comprises pooled proteins from said collected fractions.

19. (Original) The pharmaceutical composition of claim 11, wherein the chaperone protein complexes are present in aggregates that have a molecular weight that is greater than 300 kD.

20. (Original) The pharmaceutical composition of claim 19, wherein the aggregate chaperone protein complexes comprise GRP94/gp96, HSP 90, HSP70, calreticulin, BiP/grp78, grp75/mt, HSP 70, HSP72, HSP60, and HSP40.

21. (New) The method of claim 1, wherein the chaotropic agent is urea.

22. (New) The method of claim 1 or 21, wherein said free solution isoelectric focusing is performed in the presence of detergent.

23. (New) The method of claim 3, wherein said matrix comprises said chaotropic agent and a detergent.

24. (New) The method of claim 22 wherein said detergent is nonionic.

25. (New) The method of claim 23 wherein said detergent is nonionic.

26. (New) The method of claim 3 or 23 wherein said chaotropic agent is urea.

27. (New) The method of claim 26, wherein said chaotropic agent is 6 M urea.

28. (New) The method of claim 24 wherein the nonionic detergent is one or more of octylphenol ethylene oxide condensate, octylphenoxypoly (ethyleneoxy) ethanol, or (octylphenoxy) polyethoxyethanol.

29. (New) The method of claim 25 wherein the nonionic detergent is one or more of octylphenol ethylene oxide condensate, octylphenoxypoly (ethyleneoxy) ethanol, or (octylphenoxy) polyethoxyethanol.

30. (New) The method of claim 3, wherein said matrix comprises 0.5% octylphenol ethylene oxide condensate, 0.5% octylphenoxypoly (ethyleneoxy) ethanol, and 0.5% (octylphenoxy) polyethoxyethanol.

31. (New) The method of claim 28 or 29, wherein said matrix comprises 0.5% octylphenol ethylene oxide condensate, 0.5% octylphenoxypoly (ethyleneoxy) ethanol, and 0.5% (octylphenoxy) polyethoxyethanol.

32. (New) The pharmaceutical composition of claim 11, wherein said chaotropic agent is urea.

33. (New) The pharmaceutical composition of claim 32, wherein said chaotropic agent is 6 M urea.

34. (New) The pharmaceutical composition of claim 11 or 32, wherein the isoelectric focusing is performed in the presence of detergent.

35. (New) The pharmaceutical composition of claim 34, wherein said detergent is nonionic.

36. (New) The pharmaceutical composition of claim 35, wherein said nonionic detergent is one or more of octylphenol ethylene oxide condensate, octylphenoxypoly (ethyleneoxy) ethanol, or (octylphenoxy) polyethoxyethanol.

37. (New) The pharmaceutical composition of claim 36, wherein said nonionic detergent comprises 0.5% octylphenol ethylene oxide condensate, 0.5% octylphenoxypoly (ethyleneoxy) ethanol, and 0.5% (octylphenoxy) polyethoxyethanol.

38. (New) The pharmaceutical composition of claim 11, wherein the isoelectric focusing is performed in the presence of 6 M urea, 0.5% octylphenol ethylene oxide condensate, 0.5% octylphenoxypoly (ethyleneoxy) ethanol, 0.5% (octylphenoxy) polyethoxyethanol, 5 mM Tris/Cl (pH 7.4), and 5 mM NaCl.